David Min, MD
Cardiovascular Disease · Lebanon, NHNPI 1205946126
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,775 of the $3,349 with a category attached, or 82.9%. AstraZeneca accounts for 86.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $3,062 and has fallen 96.5% since, to $109 in 2021.
Across 14 payments — averaging $239.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Medtronic$291
- Nevro Corp.$35
- Amgen$27
- Siemens Medical Solutions USA, Inc.$20
- Eisai Inc.$15
- plus $53 from 4 others
What the payments were for
- Consulting fees$2,77583%
- Food & beverage$57417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $2,907 |
| Medtronic(2 entities) | 4 | $291 |
| Nevro Corp. | 1 | $35 |
| Amgen | 1 | $27 |
| Siemens Medical Solutions USA, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $14 |
| Si-bone, Inc. | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$2,907
- PIVOX Oblique Lateral Spinal System$134
- O-ARM-Spine$105
How this compares
$3,349 in reported general payments places this provider in the 75th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $50,016 |
| Repatha SureclickEvolocumab | 37 | $21,037 |
| XareltoRivaroxaban | 14 | $20,040 |
| EntrestoSacubitril/Valsartan | 15 | $12,124 |
| Metoprolol Succinate | 84 | $1,338 |
| Losartan Potassium | 79 | $903 |
| Rosuvastatin Calcium | 37 | $776 |
| Atorvastatin Calcium | 60 | $772 |
| Amlodipine Besylate | 74 | $721 |
| Valsartan | 12 | $370 |
| Potassium Chloride | 12 | $293 |
| Lisinopril | 40 | $278 |
| Carvedilol | 35 | $276 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $275 |
| Furosemide | 35 | $202 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lebanon
- Kevin KwakuLebanon$79K
- Michael YoungLebanon$53K
- Merle MyersonLebanon$15K
- Ian GilchristLebanon$13K
- Robert DangeloLebanon$10K
- Rumman SyedLebanon$9K
- Mohammadtokir MujtabaLebanon$8K
- Lauren Gilstrap MilleyLebanon$5K
- Fernando Contreras-ValdesLebanon$5K
- Monika BernasLebanon$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.